PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia

Highlights • We achieved our intended sample size of 210 participants. • Rates of ear disease (71%) and 23vPPV-type carriage (26%) were lower than expected. • We were unable to show maternal 23vPPV efficacy against infant ear disease or 23vPPV-type carriage. • 23vPPV in pregnancy halved infant ear d...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 33; no. 48; pp. 6579 - 6587
Main Authors Binks, Michael J, Moberley, Sarah A, Balloch, Anne, Leach, Amanda J, Nelson, Sandra, Hare, Kim M, Wilson, Cate, Morris, Peter S, Nelson, Jane, Chatfield, Mark D, Tang, Mimi L.K, Torzillo, Paul, Carapetis, Jonathan R, Mulholland, E. Kim, Andrews, Ross M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 27.11.2015
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Highlights • We achieved our intended sample size of 210 participants. • Rates of ear disease (71%) and 23vPPV-type carriage (26%) were lower than expected. • We were unable to show maternal 23vPPV efficacy against infant ear disease or 23vPPV-type carriage. • 23vPPV in pregnancy halved infant ear disease concurrent with 23vPPV-type carriage. • 23vPPV in pregnancy may complement childhood pneumococcal vaccination programs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.10.101